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Pancreatic a-cells secrete glucagon to maintain energy homeostasis. Although histamine has an
important role in energy homeostasis, the expression and function of histamine receptors in pan-
creatic a-cells remains unknown. We found that the histamine H3 receptor (H3R) was expressed
in mouse pancreatic a-cells and aTC1.6 cells, a mouse pancreatic a-cell line. H3R inhibited glucagon
secretion from aTC1.6 cells by inhibiting an increase in intracellular Ca2+ concentration. We also
found that immepip, a selective H3R agonist, decreased serum glucagon concentration in rats. These
results suggest that H3R modulates glucagon secretion from pancreatic a-cells.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Histamine has multiple functions; it is released during allergic
reactions, affects gastric acid secretion, and impacts the sleep–
wake cycle. These functions are mediated thorough interactions
with four different subtypes (H1–H4), which belong to the G pro-
tein-coupled receptor superfamily. Among these subtypes, hista-
mine H3 receptor (H3R) is currently a hot topic because of its
important role in energy homeostasis [1]. Neuronal histamine
has an inhibitory effect on food intake through modulation of
hypothalamic neuronal activities [2,3]. H3R expressed in the cen-
tral nervous system (CNS) regulates histamine release [4]. There-
fore, H3R is a prospective therapeutic target for obesity, which
could potentially lead to reduced body weight [5].
The regulation of glucagon secretion from pancreatic a-cells is
fundamental to the maintenance of glucose homeostasis; under
normal conditions they secrete glucagon in response to starva-
tion-induced hypoglycemia. Glucagon is a 29-amino acid peptide
hormone that elevates blood glucose concentration by glycogenol-
ysis and gluconeogenesis in the liver [6]. Glucagon secretion
from pancreatic a-cells has recently become a hot topic as anew therapeutic target for diabetes mellitus [7], as dysfunctional
pancreatic a-cells have been reported in diabetic patients [8]. In
these patients, blood glucagon concentrations are elevated even
in hyperglycemic states [9]. Conversely, glucagon secretion is
insufﬁcient in response to critical hypoglycemia [10]. This inap-
propriate glucagon secretion aggravates diabetes. Therefore, it is
crucial to understand the mechanism of glucagon secretion.
The key secretagogue for glucagon is low serum glucose con-
centration [11]. Low glucose concentrations facilitate glucagon
release from pancreatic a-cells through the activation of voltage-
dependent Ca2+ channels (VDCCs) [12]. In addition to glucose,
many paracrine/endocrine products and neurotransmitters are
involved in the modiﬁcation of glucagon secretion [13]. For exam-
ple, glucagon-like peptide (GLP)-1, an incretin secreted from the
small intestine L-cells, decreases glucagon secretion from pancre-
atic a-cells [14].
There are some biological molecules that modulate pancreatic
a-cells and CNS functions to regulate total energy homeostasis.
GLP-1 has an important role in regulating eating behavior by mod-
ulating CNS activities. Turton et al. reported that administration of
GLP-1 into the lateral ventricle resulted in inhibition of eating
behavior [15]. This evidence indicates that pancreatic a-cells and
CNS are targets of GLP-1. Additionally, leptin, a peptide adipokine
secreted from peripheral adipose tissues [16], has inhibitory effects
on pancreatic a-cells [17] and food intake [18]. Moreover, ghrelin,
a 28-amino acid peptide synthesized in the gastrointestinal tract,
directly stimulates glucagon secretion [19] and eating behavior
T. Nakamura et al. / FEBS Open Bio 5 (2015) 36–41 37[20]. As previously mentioned, hypothalamic H3R has an important
role in food intake; thus, it is interesting to examine whether H3R is
expressed in pancreatic a-cells and involved in the regulation of
energy homeostasis.
Taking this evidence into account, we hypothesize that H3R is
expressed and involved in pancreatic a-cell function. We used a
mouse pancreatic a-cell line, aTC1.6 cells, to evaluate the function
of H3R in pancreatic a-cells. These aTC1.6 cells have properties
similar to those of pancreatic a-cells, and they are widely used in
research on glucagon secretion [21]. We discovered inhibitory
effects of H3R on glucagon secretion in vitro and in vivo using phar-
macological assays.
2. Methods
2.1. Animals
Wild-type (WT) and histamine H3 receptor-gene KO (H3KO)
C57BL/6 [22] mice were bred in our laboratory. Wister rats were
purchased from Japan SLC (Hamamatsu, Japan). All mice were
maintained on a 12-h light/dark cycle in a humidity- and temper-
ature-controlled room, and they were allowed ad libitum access to
food and water. This study was approved by the Center for Labora-
tory Animal Research, Tohoku University, Sendai, Japan. This study
had been performed in accordance with the EU Directive 2010/63/
EU for animal experiments.
2.2. Cell culture
aTC1.6 cells were purchased from the American Type Culture
Collection (Manassas, VA, USA). Cells were maintained in DMEM
(Invitrogen, Carlsbad, CA, USA) containing 10% FCS (Thermo,
Waltham, MA, USA), 15 mM HEPES (Gibco, Carlsbad, CA, USA),
0.1 mM non-essential amino acids (Gibco), 0.02% BSA (Sigma, St.
Louis, MO, USA), 1.5 g/dL sodium bicarbonate (Sigma), 2 g/L
D-glucose (Sigma), 75 mg/mL penicillin G potassium (Wako, Osaka,
Japan), and 100 mg/L streptomycin sulfate (Wako) at 37 C in a
5%-CO2 humidiﬁed incubator.
2.3. RT-PCR
RT-PCR was performed using a previously described protocol
[23]. Brieﬂy, total RNA was isolated from aTC1.6 cells and
reverse-transcribed. Samples (equivalent to 5 ng total RNA) were
ampliﬁed by 35 cycles of PCR (10 s at 98 C, 30 s at 60 C, and
90 s at 72 C).
2.4. Western blot
Western blot of H3R was performed using a previously
described protocol [23]. We used the hypothalamic lysate from
WT and H3KO mice as positive and negative controls, respectively.
Beta-actin was detected by an antibody (Cell Signaling Technology,
Danvers, MA, USA) as a loading control.
2.5. Immunohistochemical analysis
Pancreata were quickly removed from 12-week-old WT and
H3KO mice. Isolated pancreata were ﬁxed in 10% paraformalde-
hyde and embedded in parafﬁn. The parafﬁn sections were depa-
rafﬁnized and blocked with 10% goat serum at room temperature
for 15 min. To detect glucagon, sections were incubated with
mouse anti-glucagon antibody (Sigma; 1:2000 dilution) for 2 h at
room temperature and then treated with the secondary antibody:
Alexa Fluor (Invitrogen) 568 conjugated goat anti-mouse antibody(1:100 dilution). To detect H3R, samples were incubated overnight
at 4 C with rabbit anti-mouse H3R antibody (4 lg/mL) [23] and
then treated with the secondary antibody: Alexa Fluor 488 conju-
gated goat anti-rabbit antibody (Invitrogen). For double staining of
glucagon and H3R, samples were incubated with anti-glucagon
antibody for 2 h at room temperature, washed thrice with PBS, fol-
lowed by overnight incubation with anti-H3R antibody at 4 C.
Specimens from H3KO mice were used as negative controls for
H3R. Finally, all samples were encapsulated with mounting med-
ium containing DAPI.
2.6. Glucagon secretion assay
aTC1.6 cells were seeded into a 24-well plate at a density of
2.0  105 cells per well and then preincubated in 500 lL of
Krebs–Ringer bicarbonate buffer (KRB) containing 20 mM glucose
for 30 min at 37 C in 5% CO2. Subsequently, aTC1.6 cells were
incubated in 500 lL of KRB containing 20 or 2.8 mM glu-
cose ± 1 lM histamine (Sigma), 1 and 100 lM of the selective
H3R agonist immepip (Sigma) [24,25], or the selective H3R inverse
agonist JNJ-5207852 (kindly gifted from Dr. Nicholas Carruthers,
Johnson & Johnson Pharmaceutical Research and Development,
USA) [26,27], or KRB containing 20 mM KCl ± 1 lM immepip, for
1 h at 37 C in 5% CO2. Immepip and JNJ-5207852 were dissolved
in distilled water. We used a glucagon ELISA kit (Wako) to measure
glucagon concentration in KRB.
2.7. Intracellular Ca2+concentration measurement
aTC1.6 cells were seeded into a 96-well plate (Greiner, Fricken-
hausen, Germany) at a density of 2.0  104 cells per well and were
then preincubated in KRB containing 20 mM glucose, 5 lM ﬂuo-4/
AM, 5 mM probenecid, and 1  Power load (all from Invitrogen) for
30 min at 37 C. Preincubated KRB was replaced with KRB contain-
ing 20 mM glucose ± 1 lM immepip and the 96-well plate was
placed into a microplate reader FlexStation 3 (Molecular Devices,
Sunnyvale, CA, USA) to record changes in ﬂuorescence (excitation:
495 nm/emission: 518 nm). Cells were excited at 495 nm and
the light emitted through a 518-nm ﬁlter was detected. After a
1-min measurement of baseline ﬂuorescence, glucose concentra-
tion in KRB in each well was diluted to 2.8 mM by adding
KRB ± 1 lM immepip from injectors, or KRB containing high
KCl ± 1 lM immepip was added from injectors to adjust KCl
concentration to 20 mM. Fluorescent intensity before ﬂuo-4/AM
loading was measured as background.
2.8. Measurement of serum glucagon concentration in rats
We used rats instead of mice to evaluate the effect of immepip
on serum glucagon concentration because a glucagon ELISA
kit required 100 lL of serum to measure glucagon correctly.
10-week-old Wister rats were fasted for 24 h prior to the experi-
ment and were anesthetized with isoﬂurane. Immepip (30 mg/
kg) dissolved in normal saline or just normal saline was adminis-
tered intraperitoneally. Blood samples were collected from the
caudal vein before injection as the baseline and at 15 min after
injection. Samples were centrifuged for 30 min at 5000 rpm at
4 C and then the supernatant plasma was collected. Plasma gluca-
gon concentration was measured using a glucagon ELISA kit
(Wako).
2.9. Data analysis and presentation
All experiments were performed in triplicate. Statistical analy-
sis was performed using Student’s t-test or one-way ANOVA. Data
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signiﬁcant.3. Results
3.1. H3R were expressed in aTC1.6 cells
First, we examined the expression of histamine receptors in
aTC1.6 cells using RT-PCR and western blot. H3R mRNA wasA
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Glucagon secretion from pancreatic a-cells is vital to enhance
serum glucose concentration in hypoglycemia [6]. We investigated
effects of histamine on glucagon secretion from aTC1.6 cells. Glu-
cagon secretion increased 1.41-fold over basal concentration in
response to low glucose concentrations (Fig. 2A). This secretion
associated with low glucose concentrations was remarkably inhib-
ited by 1 lM histamine (0.67 ± 0.05 ng/well/h versus 0.96 ± 0.07
ng/well/h, P < 0.05), while basal secretion at 20 mM glucose with
histamine was maintained at close to control concentrations
(0.68 ± 0.06 ng/well/h versus 0.68 ± 0.06 ng/well/h, P > 0.05;
Fig. 2A). These results indicate that histamine negatively regulates
glucagon secretion from aTC1.6 cells in response to low glucose
concentration.
Subsequently, we examined the role of H3R expressed in aTC1.6
cells in glucagon secretion using pharmacological assays with the
H3R agonist immepip or the inverse agonist JNJ-5207852. Glucagon
secretion associated with low glucose concentrations was
remarkably inhibited by 1 lM immepip (0.73 ± 0.08 ng/well/h
versus 1.01 ± 0.10 ng/well/h, P < 0.05; Fig. 2B). Conversely, 1 lM
JNJ-5207852 increased glucagon secretion (1.83 ± 0.08 ng/well/hA
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Fig. 2. Effects of histamine, immepip, or JNJ-5207852 on glucagon secretion from
aTC1.6 cells. (A) Glucagon secretion from aTC1.6 cells at low (2.8 mM) and high
(20 mM) glucose concentrations ± 1 lM histamine. ⁄P < 0.05, n = 6. (B) Glucagon
secretion from aTC1.6 cells at low (2.8 mM) and high (20 mM) glucose concentra-
tions ± 1 or 100 lM immepip. ⁄P < 0.05, n = 6. (C) Glucagon secretion from aTC1.6
cells at low (2.8 mM) and high (20 mM) glucose concentrations ± 1 or 100 lM JNJ-
5207852. ⁄P < 0.05, n = 6.versus 1.36 ± 0.21 ng/well/h, P < 0.05; Fig. 2C). These results indicate
that H3R inhibits glucagon secretion in aTC1.6 cells.
3.3. Immepip inhibited the increase of intracellular Ca2+ concentration
H3R activation modulates cellular functions through several
intracellular signaling pathways downstream of H3R [28,29]. Silver
et al. reported that H3R activation attenuated norepinephrineB
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Fig. 3. Analysis of intracellular signaling in aTC1.6 cells. (A) Changes in intracellular
Ca2+ concentration in response to low (2.8 mM) glucose concentration ± 1 lM
immepip. The average of ﬂuorescence intensity from ﬂuo-4 before low glucose
stimulation was arbitrarily set as 1. Intensity ratio on y-axis relates to the increase
of intracellular Ca2+ concentration in direct proportion. 20 G: 20 mM glucose, 2.8 G:
2.8 mM glucose, n = 4. (B) Glucagon secretion from aTC1.6 cells at high (20 mM)
glucose concentration and high (20 mM) KCl concentration ± 1 lM immepip.
⁄P < 0.05, n = 6. (C) Changes in intracellular Ca2+ concentration in response to high
(20 mM) KCl concentration ± 1 lM immepip. The average of ﬂuorescence intensity
from ﬂuo-4 before low glucose stimulation was arbitrarily set as 1. Intensity ratio
on y-axis relates to the increase of intracellular Ca2+ concentration in direct
proportion. 20 G: 20 mM glucose, 20 K: 20 mM KCl, n = 4.
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Fig. 4. Effects of immepip on rat plasma glucagon concentration. Serum glucagon
concentration of rats before and 15 min after intraperitoneal injection of 30 mg/kg
immepip. ⁄P < 0.05, n = 4.
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tion, seemingly because of an impaired entrance of Ca2+ through
VDCCs [30]. Glucagon exocytosis from pancreatic a-cells also
requires an increase in intracellular Ca2+ concentration [31,32].
Thus, we examined the effect of activated H3R on intracellular
Ca2+ concentration. One micromole of immepip impaired the
increase in intracellular Ca2+ concentration in response to
2.8 mM glucose (transient changes in Ca2+; 0.36 ± 0.03 versus
0.47 ± 0.04; Fig. 3A). This result indicates that H3R is involved in
the regulation of intracellular Ca2+ concentration in aTC1.6 cells.
To conﬁrmwhether intracellular Ca2+ concentration has a direct
role in the inhibitory effect of H3R on glucagon secretion, we stim-
ulated aTC1.6 cells with 20 mM KCl solution, which directly depo-
larized plasma membranes, followed by Ca2+ inﬂux through
activated VDCCs [33]. We examined the effect of immepip on glu-
cagon secretion stimulated by 20 mM KCl and found that glucagon
secretion in response to 20 mM KCl was reduced by 1 lM immepip
(1.82 ± 0.07 ng/well/h versus 2.29 ± 0.15 ng/well/h; Fig. 3B). This
result suggests that intracellular signaling from H3R affects the
increase in intracellular Ca2+ concentration and/or downstream
Ca2+ signaling, so we examined effects of immepip on the increase
in intracellular Ca2+ concentration in response to 20 mM KCl. One
micromole of immepip impaired the increase in intracellular Ca2+
concentration in response to 20 mM KCl (transient changes in
Ca2+; 0.13 ± 0.07 versus 0.55 ± 0.08; Fig. 3C). These results indicate
that H3R signaling exerted an inhibitory effect on glucagon secre-
tion through the blockage of Ca2+ inﬂux.
3.4. H3R agonist reduced serum glucagon concentration in rats
Finally, we investigated the role of H3R in glucagon secretion
in vivo. We examined the effect of immepip on serum glucagon
concentration in rats. Serum glucagon concentration after a 24-h
fast was remarkably inhibited by 1 lM immepip (75.3 ± 14.5 pg/
mL versus 130.0 ± 12.8 pg/mL, P < 0.05; Fig. 4), indicating that
H3R was involved in the regulation of serum glucagon concentra-
tion in vivo.
4. Discussion
We demonstrated for the ﬁrst time that H3R is expressed in
aTC1.6 cells and mouse pancreatic a-cells. Using RT-PCR and wes-
tern blot analysis, aTC1.6 cells were shown to express H3R mRNA
and protein (Fig. 1A, B). H3R protein expression in pancreatic
a-cells was conﬁrmed by immunohistochemical analysis. Our data
showed that activated H3R inhibited glucagon secretion from
aTC1.6 cells in response to low glucose concentrations (Fig. 2).
H3R is coupled to Gi protein [34]. Previous reports revealed that
several Gi protein-coupled receptors expressed in pancreatic
a-cells inhibited glucagon secretion. For example, group III metab-
otropic glutamate receptors, coupled with inhibitory Gi protein, areexpressed in rat pancreatic a-cells and inhibit glucagon secretion
from rat islets under low glucose conditions [35]. Moreover,
somatostatin from pancreatic d-cells also inhibits glucagon secre-
tion through somatostatin receptor 2 coupled to Gi proteins [36].
This evidence corroborates the function of H3R in pancreatic
a-cells.
To elucidate the regulatory mechanism of H3R on glucagon
secretion, we investigated effects of immepip on intracellular
Ca2+ concentration, which is essential to glucagon secretion [13].
Immepip inhibited increases in intracellular Ca2+ concentrations
in response to 20 mM KCl stimulation (Fig. 3B). KCl stimulation
directly elicits plasma membrane depolarization, leading to the
activation of VDCCs. It is possible that H3R signaling might inhibit
the activity of VDCCs in pancreatic a-cells because H3R in neurons
reduced Ca2+ inﬂux through VDCCs [37]. However, the inhibitory
effect of immepip on Ca2+ concentration was more moderate dur-
ing low glucose conditions than during KCl stimulation (Fig. 3B, C),
although immepip inhibited glucagon secretion during low glucose
conditions more strongly than during KCl stimulation (Figs. 2B and
3A). This suggests that the intracellular Ca2+-independent signaling
pathway might be associated with the inhibitory effect of H3R on
glucagon secretion. Recently, De Marinis showed that the cAMP-
PKA pathway increased glucagon secretion by the recruitment of
glucagon granules toward the cell membrane [38]. Activated H3R
inhibits the cAMP-PKA pathway [24,39]; thus, any involvement
of this pathway might be conﬁrmed by using gene silencing tech-
nologies or a pharmacological approach. Further studies are neces-
sary to elucidate the signaling induced by H3R stimulation in
pancreatic a-cells.
Immepip remarkably inhibited plasma glucagon concentration
15 min after intraperitoneal injection, indicating that H3R has an
important role in glucagon concentration in vivo. Our data suggests
that immepip acts on pancreatic a-cells leading to direct inhibition
of glucagon secretion. Additionally, immepip might indirectly
modulate glucagon secretion through sympathetic nerves. Sympa-
thetic nerve endings innervate pancreatic a-cells and modulate
glucagon secretion [32,40]. Schlicker et al. reported that postgan-
glionic sympathetic nerves expressed H3R and that this H3R regu-
lates neurotransmitter release [41]. This evidence indicates that
immepip might act on H3R in sympathetic nerves and indirectly
regulate glucagon secretion. However, further studies are needed
to elucidate the role of H3R in pancreatic a-cells or sympathetic
nerves in the regulation of serum glucagon secretion.
As previously mentioned, abnormal glucagon secretion from
pancreatic a-cells has been observed in diabetic patients [8]. H3R
agonists that decrease glucagon secretion could improve excessive
glucagon secretion in hyperglycemic conditions; however, our data
only indicates the inhibitory effect of H3R on glucagon secretion in
hypoglycemic conditions. Therefore, further studies are needed to
clarify therapeutic effects of H3R agonists in diabetic animal mod-
els, which have abnormal glucagon secretion during hyperglyce-
mia [42].
We found a weak band of H1R mRNA in aTC1.6 cells (Fig. 1A).
Based on our previous study that clearly indicated the absence of
H1R mRNA in pancreatic islets [23], its expression might be unde-
tectably low or absent in pancreatic islets and it may be speciﬁc to
the cell-line. Additionally, we conﬁrmed that glucagon secretion
was not affected by H1R-speciﬁc agonists (data not shown).
Accordingly, it is suggested that H1R is not involved in the regula-
tion of glucagon secretion in pancreatic a-cells.
In this study, we found that H3R in pancreatic a-cells had an
inhibitory effect on glucagon secretion possibly by decreasing
intracellular Ca2+ concentration. We also found that H3R was
involved in glucagon secretion in vivo. It will be interesting to
investigate roles of H3R in glucagon secretion in a diabetic animal
model.
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